InsiderTrades.com logo
Kevin J. Ballinger net worth and biography
  • Phone
  • Email
  • Website

Kevin Ballinger Biography and Net Worth

Director of Silk Road Medical

Mr. Ballinger has served as a member of our Board of Directors since December 2020. From July 2020 to September 2023, Mr. Ballinger served as President of Aldevron, LLC (“Aldevron”), a privately held genomics company that was acquired by Danaher Corporation (“Danaher”) in August 2021. Prior to joining Aldevron, he spent 25 years at Boston Scientific Corporation (“Boston Scientific”), a publicly traded global company focused on a variety of interventional medical specialties. During his last nine years at Boston Scientific, Mr. Ballinger served as Executive Vice President and Global President of the Interventional Cardiology division. Mr. Ballinger has served on the board of directors of Shockwave Medical, Inc., a medical device company, since June 2023. Mr. Ballinger earned his B.S. in Mechanical Engineering from Michigan Technological University, and his M.B.A. from the University of Minnesota’s Carlson School of Management. Mr. Ballinger’s healthcare industry experience provides him with the qualifications and skills to serve on our Board of Directors.

What is Kevin J. Ballinger's net worth?

The estimated net worth of Kevin J. Ballinger is at least $489,514.43 as of March 5th, 2024. Mr. Ballinger owns 17,807 shares of Silk Road Medical stock worth more than $489,514 as of May 29th. This net worth evaluation does not reflect any other assets that Mr. Ballinger may own. Learn More about Kevin J. Ballinger's net worth.

How do I contact Kevin J. Ballinger?

The corporate mailing address for Mr. Ballinger and other Silk Road Medical executives is 1213 INNSBRUCK DR., SUNNYVALE CA, 94089. Silk Road Medical can also be reached via phone at (408) 720-9002 and via email at investors@silkroadmed.com. Learn More on Kevin J. Ballinger's contact information.

Has Kevin J. Ballinger been buying or selling shares of Silk Road Medical?

Kevin J. Ballinger has not been actively trading shares of Silk Road Medical over the course of the past ninety days. Most recently, on Tuesday, March 5th, Kevin J. Ballinger bought 11,700 shares of Silk Road Medical stock. The stock was acquired at an average cost of $16.99 per share, with a total value of $198,783.00. Following the completion of the transaction, the director now directly owns 17,807 shares of the company's stock, valued at $302,540.93. Learn More on Kevin J. Ballinger's trading history.

Who are Silk Road Medical's active insiders?

Silk Road Medical's insider roster includes Kevin Ballinger (Director), Lucas Buchanan (CFO), Andrew Davis (Insider), Kevin Klemz (EVP), Jack Lasersohn (Director), Erica Rogers (CEO), Richard Ruedy (EVP), and Elizabeth Weatherman (Director). Learn More on Silk Road Medical's active insiders.

Are insiders buying or selling shares of Silk Road Medical?

In the last twelve months, insiders at the sold shares 2 times. They sold a total of 2,334 shares worth more than $63,244.80. The most recent insider tranaction occured on August, 19th when EVP Kevin M Klemz sold 2,268 shares worth more than $61,462.80. Insiders at Silk Road Medical own 3.9% of the company. Learn More about insider trades at Silk Road Medical.

Information on this page was last updated on 8/19/2024.

Kevin J. Ballinger Insider Trading History at Silk Road Medical

See Full Table

Kevin J. Ballinger Buying and Selling Activity at Silk Road Medical

This chart shows Kevin J Ballinger's buying and selling at Silk Road Medical by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$100k$0$100kTotal Insider BuyingTotal Insider Selling

Silk Road Medical Company Overview

Silk Road Medical logo
Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.
Read More

Today's Range

Now: $27.49
Low: $27.49
High: $27.49

50 Day Range

MA: $27.31
Low: $27.01
High: $27.50

2 Week Range

Now: $27.49
Low: $6.08
High: $27.51

Volume

N/A

Average Volume

1,200,763 shs

Market Capitalization

$1.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.53